RecruitingAdvanced Solid TumorsEwing SarcomaHepatocellular Carcinoma (HCC)
A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies
Eligible age
16+ yrs
Accepts
All genders
Locations
4 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
A Phase 1/1B Study of ST-01156 in Patients with Advanced Solid Malignancies
Sponsor: SEED Therapeutics, Inc.
You may qualify if…
- ✓ Age ≥ 18 years on the day of signing the consent form, except for adolescents with Ewing Sarcoma or other malignancies for which there is a biological rationale to support participation, in which case the participant is ≥ 16 years old.
- ✓ Has a metastatic or locally advanced and unresectable solid tumor.
- ✓ Has at least 1 measurable lesion or evaluable disease per RECIST v1.1.
- ✓ Has an ECOG performance status ≤ 2 at screening.
- ✓ Has adequate organ function as defined in the protocol.
You may not qualify if…
- ✕ Has received prior radiotherapy within 2 weeks of treatment.
- ✕ Has known active CNS metastases and/or carcinomatous meningitis. Participants with previously treated brain metastases may participate, provided they are radiologically stable
- ✕ Has received treatment with any local or systemic anticancer therapy or investigational anticancer agent within 14 days or 5 half-lives, whichever is shorter.
- ✕ Had major surgery within 28 days before study therapy administration
- ✕ Has toxicities from previous anticancer therapies that have not resolved to baseline levels, with the exception of alopecia and peripheral neuropathy.
- ✕ Has previously received a RBM39 inhibitor/degrader.
Where it's recruiting
Source: ClinicalTrials.gov · NCT07197554 · last updated 2026-06-02